Lipocine Issuance Purchase of Equity Shares vs Capital Expenditure Analysis
LPCN Stock | USD 4.44 0.36 7.50% |
Trend analysis of Lipocine balance sheet accounts such as Total Stockholder Equity of 24.6 M provides information on Lipocine's total assets, liabilities, and equity, which is the actual value of Lipocine to its prevalent stockholders. By breaking down trends over time using Lipocine balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Lipocine |
About Lipocine Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Lipocine at a specified time, usually calculated after every quarter, six months, or one year. Lipocine Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Lipocine and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Lipocine currently owns. An asset can also be divided into two categories, current and non-current.
Lipocine Balance Sheet Chart
Lipocine Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Lipocine uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Lipocine's Cash And Short Term Investments are very stable compared to the past year. As of the 25th of April 2024, Common Stock Total Equity is likely to grow to about 10.7 K, while Other Liabilities is likely to drop about 196.5 K. Add Fundamental
Total Assets
Total assets refers to the total amount of Lipocine assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lipocine books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Lipocine balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Lipocine are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Lipocine's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lipocine current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.At this time, Lipocine's Selling General Administrative is very stable compared to the past year. As of the 25th of April 2024, Sales General And Administrative To Revenue is likely to grow to 46.82, while Tax Provision is likely to drop 411.40.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 5.3M | 4.1M | 15.1M | 15.8M | Cost Of Revenue | 7.7M | 8.6M | 28.7K | 27.2K |
Lipocine fundamental ratios Correlations
Click cells to compare fundamentals
Lipocine Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lipocine fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 19.7M | 25.4M | 52.5M | 37.5M | 23.0M | 29.7M | |
Other Current Liab | 449.3K | 1.7M | 1M | 1.1M | 1.2M | 1.5M | |
Total Current Liabilities | 5.0M | 6.6M | 5.6M | 1.7M | 2.6M | 3.4M | |
Total Stockholder Equity | 6.3M | 15.3M | 45.6M | 35.6M | 20.4M | 24.6M | |
Net Debt | (2.6M) | (13.6M) | (639.7K) | (3.1M) | (4.8M) | (5.0M) | |
Retained Earnings | (151.1M) | (172.0M) | (172.7M) | (183.4M) | (199.8M) | (189.8M) | |
Accounts Payable | 1.2M | 1.6M | 1.3M | 600.4K | 1.4M | 798.8K | |
Cash | 9.7M | 19.2M | 3.0M | 3.1M | 4.8M | 9.2M | |
Cash And Short Term Investments | 14.1M | 19.7M | 44.6M | 32.5M | 22.0M | 26.6M | |
Common Stock Total Equity | 2.2K | 3.8K | 7.0K | 8.8K | 10.2K | 10.7K | |
Common Stock Shares Outstanding | 1.5M | 3.3M | 5.1M | 5.2M | 5.3M | 5.5M | |
Liabilities And Stockholders Equity | 19.7M | 25.4M | 52.5M | 37.5M | 23.0M | 29.7M | |
Other Current Assets | 545.9K | 661.3K | 1.5M | 945.3K | 773.4K | 1.0M | |
Other Stockholder Equity | 157.4M | 187.4M | 218.2M | 219.1M | 220.1M | 147.6M | |
Total Liab | 13.4M | 10.0M | 6.9M | 1.9M | 2.6M | 5.1M | |
Total Current Assets | 19.6M | 25.3M | 46.4M | 34.1M | 22.9M | 28.8M | |
Accumulated Other Comprehensive Income | (963.0) | (38.0) | (18.0K) | (20.3K) | 7.3K | 7.6K | |
Common Stock | 3.8K | 7.0K | 8.8K | 8.9K | 8.9K | 9.3K | |
Property Plant Equipment | 19.0K | 3.6K | 7.2K | 131.6K | 118.4K | 124.4K | |
Net Tangible Assets | 6.3M | 15.3M | 45.6M | 35.6M | 41.0M | 27.0M | |
Retained Earnings Total Equity | (138.1M) | (151.1M) | (172.0M) | (172.7M) | (155.4M) | (163.2M) | |
Short Term Investments | 4.3M | 450.0K | 41.7M | 29.4M | 17.3M | 15.1M | |
Capital Surpluse | 147.5M | 157.4M | 187.4M | 218.3M | 251.0M | 143.4M | |
Property Plant And Equipment Net | 3.6K | 0.0 | 7.2K | 131.6K | 116.1K | 63.4K | |
Non Current Assets Total | 27.3K | 23.8K | 6.1M | 3.4M | 139.8K | 132.9K | |
Property Plant And Equipment Gross | 3.6K | 1.1M | 1.2M | 1.3M | 1.3M | 1.4M | |
Net Receivables | 16.5K | 391.0 | 247.3K | 659.9K | 52.3K | 49.6K | |
Net Invested Capital | 13.4M | 20.9M | 47.9M | 35.6M | 20.4M | 27.8M | |
Net Working Capital | 14.7M | 18.7M | 40.8M | 32.5M | 20.2M | 25.5M | |
Short Long Term Debt Total | 7.1M | 5.6M | 2.3M | 17.2K | 15.4K | 14.7K | |
Capital Stock | 3.8K | 7.0K | 8.8K | 8.9K | 8.9K | 7.2K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Lipocine Stock analysis
When running Lipocine's price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.14) | Revenue Per Share (0.54) | Quarterly Revenue Growth (1.00) | Return On Assets (0.37) | Return On Equity (0.58) |
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.